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Abstract
Purpose PETwith 18F-FDG has the potential to assess vascu-
lar macrophage metabolism. 18F-FDG is most often used in
combination with contrast-enhanced CT to localize increased
metabolism to specific arterial lesions. Novel 18F-FDG PET/
MRI hybrid imaging shows high potential for the combined
evaluation of atherosclerotic plaques, due to the superior mor-
phological conspicuity of plaque lesions. The purpose of this
study was to evaluate the reliability and accuracy of 18F-FDG
PET/MRI uptake quantification compared to PET/CT as a
reference standard in patients with carotid atherosclerotic
plaques.
Methods The study group comprised 34 consecutive oncolog-
ical patients with carotid plaques who underwent both PET/
CT and PET/MRI with 18F-FDG on the same day. The pres-
ence of atherosclerotic plaques was confirmed by 3 T MRI
scans. Maximum standardized uptake values (SUVmax) for
carotid plaque lesions and the average SUVof the blood pool
within the adjacent internal jugular vein were determined and
target-to-blood ratios (TBRs, plaque to blood pool) were
calculated.
Results Atherosclerotic lesions with maximum colocalized
focal FDG uptake were assessed in each patient. SUVmax
values of carotid plaque lesions were significantly lower on
PET/MRI than on PET/CT (2.3±0.6 vs. 3.1±0.6; P<0.01),
but were significantly correlated between PET/CT and PET/
MRI (Spearman’s r=0.67, P< 0.01). In contrast, TBRmax
values of plaque lesions were similar on PET/MRI and on
PET/CT (2.2±0.3 vs. 2.2±0.3; P=0.4), and again were sig-
nificantly correlated between PET/MRI and PET/CT
(Spearman’s r=0.73, P<0.01). Considering the increasing
trend in SUVmax and TBRmax values from early to delayed
imaging time-points on PET/CT and PET/MRI, respectively,
with continuous clearance of radioactivity from the blood, a
slight underestimation of TBRmax values may also be expect-
ed with PET/MRI compared with PET/CT.
Conclusion SUVmax and TBRmax values are widely accepted
reference parameters for estimation of the radioactivity of ath-
erosclerotic plaques on PET/CT. However, due to a systematic
underestimation of SUVmax and TBRmax with PET/MRI, the
optimal cut-off values indicating the presence of inflamed
plaque tissue need to be newly defined for PET/MRI.
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Introduction
An excessively high rate of sudden death due to cerebrovas-
cular diseases in apparently healthy individuals without prior
symptoms has been reported [1]. The most frequent cause is a
sudden rupture of an unstable atherosclerotic plaque, which
results in either thrombotic occlusion at the site of rupture or
distal embolization [2, 3]. It remains a major challenge for
preventative medicine to identify high-risk patients who
would benefit from intervention prior to a rupture of a nascent
plaque. In the evaluation of atherosclerotic plaques, the thin
cap fibroatheroma is recognized as the plaque type with the
highest risk of rupture [4]. On conventional imaging, MRI,
because of its excellent soft tissue contrast, provides the
unique potential to identify most of the pathomorphological
key features of vulnerable carotid plaques.
One of the primary determinants of atherosclerotic plaque
ruptures is inflammation, which leads to a high number of
strokes and myocardial infarctions [5]. PET is a method for
investigating the pathophysiology and propagation of diseases
with the help of radiotracers [6, 7]. Numerous metabolic and
pathophysiological biomarkers associated with plaque vulner-
ability have been investigated as targets for PET imaging.
Among them, 18F-FDG is the PET tracer that is most com-
monly used to assess inflamed plaques by evaluating the cor-
responding glucose metabolism [8–11], particularly of resi-
dent macrophages, which most avidly accumulate 18F-FDG.
However, PET imaging is limited by a relatively low spatial
resolution, and thus the use of morphological imaging is
needed to localize the tracer uptake [12], which can be pro-
vided by dual modality imaging systems such as PET/CT and
PET/MRI. PET/CT allows fast data acquisition and the CT
dataset can be reliably used as a transmission scan for attenu-
ation correction (AC) of the PET data [13]. It has also been
shown that vessel calcifications on non-contrast CT scans cor-
relate significantly with the patient’s overall plaque burden
[14].
With regard to characterization of arterial plaques, MRI
possesses several inherent advantages over CT, including
higher spatial resolution, an excellent soft tissue contrast,
and a lack of ionizing radiation. Furthermore, in the setting
of PET/MRI hybrid imaging, PET and MRI can be performed
simultaneously, which enables real-time MRI motion and
partial-volume correction of the PET data. Therefore, the com-
bination of 3-TMRI with simultaneous PET imaging for com-
prehensive evaluation of carotid plaques has great potential
[15], but with the caveat of suboptimal PET AC based on
MRI (MR-AC) [16]. The MR signal intensity is not propor-
tional to the amount of gamma photon attenuation [17, 18], so
that MR-AC is more challenging than CT-AC. Previous re-
search has demonstrated a significant correlation of the tracer
uptake ratio from PET using MR-AC with the ratio from PET
using CT-AC in head and neck cancer [19]. Nevertheless,
reliable quantification of vessel wall inflammation by PET/
MRI has not yet been demonstrated. The maximum standard-
ized uptake value (SUVmax) is the most commonly used value
for quantification of radioactivity on PET. In addition, the
target-to-blood pool ratio (TBR) is widely accepted for mea-
suring the inflammatory activity of atherosclerotic plaques on
PET [11].
In the present study of patients with carotid atherosclerotic
plaques, we examined the accuracy and reliability of clinical
PET/MR imaging, based on the SUVand TBR values in com-
parison to PET/CT as reference.
Materials and methods
Patients
We reviewed PET/CT and PET/MR imaging studies in 247
oncological patients who underwent both procedures for stag-
ing and restaging of different cancer types between
March 2014 and March 2015. Of these patients, 34 showed
colocalized focal uptake (TBR ≥1.6) at the carotid bifurcation
on both PET/CT and PET/MRI, and were included in this
study. Baseline data for the study patients, including type of
cancer, age, gender, BMI, blood sugar concentration and dia-
betes, are presented in Table 1. This retrospective image anal-
ysis was approved by the local ethics committee. For identifi-
cation of patients with carotid plaque lesions, MR image sets
from PET/MRI were used.
PET/CT imaging
All patients underwent an 18F-FDG PET/CT scan on a dedi-
cated PET/CTsystem (Siemens Biograph TPTV 64; Siemens,
Knoxville, TN) consisting of an LSO-based full-ring PET
scanner and a 64-row multidetector CT scanner. In 30 patients
(88 %) contrast medium was injected for the CT scan. On the
Table 1 Baseline characteristics of the study population
Characteristic Value
No. of patients 34
Age (years), mean ± SD (range) 61± 9 (52 – 84)
Male, n (%) 23 (64)
Body mass index (kg/m2), mean ± SD (range) 26± 3.9 (19 – 31)
Plasma glucose (mg/dL), mean ± SD (range) 104 ± 15 (71 – 128)
Diabetes, n (%) 3 (8)
Cancer type, n (%)
Lymphoma 27 (79)
Head and neck cancer 4 (12)
Thyroid cancer 3 (9)
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day of the scan, patients fasted for at least 6 h; their mean
glucose level was 103 ± 14.4 mg/dL (range 71 – 128 mg/
dL). 18F-FDG was injected intravenously at 4.2±0.9 MBq/
kg body weight (range 3.3 – 5.5 MBq/kg). After an uptake
period of 74±13 min (range 47 – 92 min), transmission data
were acquired from the base of the skull or the vertex to the
proximal thighs. PET emission data were then acquired in 3D
mode with a 168×168 matrix (pixel size 4.2 mm) with an
emission time of 3 min per bed position. After decay and
scatter correction, PET data were reconstructed iteratively,
applying point-spread function (PSF) correction (TrueX algo-
rithm) using four iterations and 21 subsets. The CT data were
used for AC.
PET/MR imaging
After PET/CT, 18F-FDG PET/MR imaging was performed on
a Biograph mMR system (Siemens Healthcare, Erlangen,
Germany) incorporating a 3-T MRI scanner. The PET/MRI
acquisition was started 140±21 min (range 100 – 189 min)
after administration of 18F-FDG. PET/MR images were ac-
quired in four or five bed positions with 5 min per bed posi-
tion. The MR imaging component was performed with an
integrated radiofrequency coil and a multistation protocol,
with a slice thickness of 2 mm. AC was performed using the
implemented standard four-compartment model attenuation
map calculated from a Dixon-based VIBE (volumetric inter-
polated breath-hold examination) sequence. A 3D ordinary
Poisson ordered subsets expectation maximization (OP-
OSEM) algorithm with PSF correction with three iterations
and 21 subsets was used for reconstruction. The image matrix
size was 172× 172 (pixel size 4.2 mm). The images were
smoothed with a 3-mm full-width at half-maximum
(FWHM) gaussian filter.
Image analysis
Automatic image orientation, 3D image fusion, and image
analysis for both PET/MRI and PET/CTwere performed with
commercially available software (Hermes Hybrid 3D; Hermes
Medical Solutions, Stockholm, Sweden). In a first step, two
cardiovascular radiology specialists blinded to the patients’
clinical information visually evaluated the MR images (T1-
weighted VIBE Dixon sequence) for the presence of plaques
at the left and right carotid artery bifurcation. In a second step,
two nuclear medicine physicians blinded to the clinical infor-
mation determined colocalized focal uptake of 18F-FDG on
both PET/CT and PET/MRI for the visualized carotid plaque
lesions. To assess the reproducibility of the SUVs obtained, all
lesions were reassessed by the same physicians after 3 weeks.
In a third step, SUVmax values of carotid plaques were obtain-
ed for both PET/CT and PET/MRI using a region-of-interest
(ROI) approach. To calculate TBRs, respective SUVmax
values were corrected for background blood-pool activity,
which was calculated as the mean SUV of four ROIs within
the lumen of both (left and right) internal jugular veins and
both (left and right) external jugular veins. Carotid plaques
detectable on both sides were detected in 12 patients. In those
patients, contralateral ROI analysis was performed for the less
prominent atherosclerotic bifurcation region. Correction for
radioactive decay was applied automatically by the system
for both PET/CT and PET/MRI based on the injection time.
The circulation time of 18F-FDG is a major factor that can
influence the SUV and TBR values within plaques. We per-
formed a regression analysis to evaluate the relationship be-
tween the plaque and blood pool uptake ratios.
Statistical methods
SPSS version 22.0 (IBM, Armonk, NY) was used for statisti-
cal analysis. Continuous variables with a normal distribution
were recorded as means± standard deviation. Spearman’s cor-
relation coefficient was used to assess the association between
PET/CT and PET/MRI SUVs and TBR values. Intraclass cor-
relation coefficients (ICCs) with 95 % confidence intervals
were calculated to test interobserver and intraobserver agree-
ment for TBR. Two-way random ICCs greater than 0.8 were
accepted as indicating excellent reproducibility. Group com-
parisons were made using one-way ANOVA. P values less
than 0.05 were considered statistically significant.
Regression analyses for the SUVmax and TBRmax of carotid
plaques on PET/CT and PET/MRI with circulation time were
performed. Bland Altman analysis was used to assess agree-
ment between the two measurements. Data are presented as
means± standard deviations with range.
Results
Detection of carotid plaques
Carotid plaques were detected in 52 patients from the MR
images with T1-weighted turbo spin-echo (TSE) sequences
in the neck and head region. Of these patients, 34 with
colocalized focal uptake (TBR ≥1.6) on both PET/CT and
PET/MRI were included in this study. The carotid plaque
lesion in each of these 34 patients with the highest focal up-
take was assessed on PET/CT and PET/MRI. Calcified spots
(≥200 HU) were detected on carotid plaques in five patients
using CT. Representative images are shown in Fig. 1.
Quantitative analysis of PET data from PET/CT
and PET/MRI
The mean 18F-FDG SUVmax of carotid plaques on PET/MRI
was significantly lower than the value on PET/CT, but the
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values on PET/MRI and PET/CTwere significantly correlated
(Spearman’s r=0.67, P<0.01; Table 2). Blood-pool uptake
was higher on PET/CT (1.4±0.3, range 0.9 – 2.0) than on
PET/MRI (1.1±0.2, range 0.8 – 1.7; P=0.1) due to clearance
of 18F-FDG from the blood over time.
In contrast, there was no significant difference between the
mean TBRmax values of plaque lesions on PET/CT and PET/
MRI, and the correlation of TBRmax values between PET/CT
and PET/MRI was even better (Spearman’s r=0.73, P<0.01;
Table 3). The linear regression correlation coefficients (R) for
the uptake values obtained from the two systems were 0.75 for
SUVmax and 0.73 for TBRmax (Fig. 2a, b). Bland Altman
analysis was used to assess agreement between the two mea-
surements, with a lower bias for TBRmean (−0.07) than the
bias for SUVmean (0.8) between PET/CT and PET/MRI, cor-
responding to a zero difference (Fig. 2c, d). In the assessment
of individual patients, the SUVmax values from the PET/CT
images were higher than those from the PET/MR images in all
patients (Fig. 3a). However, in 20 patients, the TBRmax value
from the PET/MR images was higher than that from the PET/
CT images (Fig. 3b).
A comprehensive group analysis comparing patients with
TBR(PET/CT) <TBR(PET/MRI) (group 1, n=20) and pa-
tients with TBR(PET/CT) ≥ TBR(PET/MRI) (group 2,
n=14) was performed (Table 4), which demonstrated a lower
blood-pool activity in group 1 with a longer average circula-
tion time on PET/MR scans, and patients in group 1 had
Fig. 1 Fused PET/CT (a–f) and PET/MRI (g–l) images of the right
carotid artery in a 52-year-old patient with a head and neck tumour
(blue circles ROIs of a plaque at the carotid bifurcation). The right
carotid artery shows focal pathological 18F-FDG uptake on the PET
images with CT-based attenuation correction. Colocalized focal uptake
of 18F-FDG is seen on the PET image with MR attenuation correction
Table 2 Comparison of mean SUVmax values from PET/CT and PET/
MRI for the 34 carotid plaque lesions
SUVmax Spearman’s r P value
a
Mean ± SD Range
PET/CT 3.1 ± 0.6 2.2 – 4.7 0.67 0.01
PET/MRI 2.3 ± 0.6 1.7 – 4.5
a One-way ANOVA
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slightly higher mean SUVmax and TBRmax on PET/MR scans.
In 12 patients, a significantly higher uptake was detected on
the plaque side than on the less prominent side on both PET/
CT and PET/MRI; likewise, significantly higher TBR values
were obtained for plaque lesions than for less prominent le-
sions on both PET/CT and PET/MRI (Table 5).
In the regression analyses between uptake value and circu-
lation time on PET/CT and PET/MRI, both SUVmax and
TBRmax in the plaque showed an up-trend from the early time
to the later time on the PET/CT and PET/MRI, respectively,
and continued clearance of blood was observed as well
(Fig. 4).
Intraclass correlation coefficients
There were excellent interobserver (R=0.87) and intraobserver
(R=0.96) correlations, along with 95 % confidence intervals
for 18F-FDG SUVs.
Discussion
Among cardiovascular imaging modalities, MRI has emerged
as a powerful tool for the assessment of the composition of
plaques, while PET has been investigated widely in cardio-
vascular disease because it offers functional quantitative infor-
mation at the molecular level [20, 21]. In the present study, we
compared the quantification of glucose uptake in carotid
plaque lesions on PET/MRI, with PET/CT as the standard of
Table 3 Comparison between TBRmax values from PET/CT and PET/
MRI for the 34 carotid plaque lesions
TBRmax Spearman’s r P value
a
Mean ± SD Range
PET/CT 2.2 ± 0.3 1.7 – 2.7 0.73 0.3
PET/MRI 2.2 ± 0.3 1.6 – 2.8
a One-way ANOVA
Fig. 2 a, b Linear regression analysis of SUV (a) and TBR (b) for 34
carotid plaques obtained on 18F-FDG PET/MRI and 18F-FDG PET/CT. c,
dBlandAltman analysis of the agreement between the two systems (SUV
and TBR on PET/CT minus SUV and TBR on PET/MRI, with a lower
bias of −0.07 for TBRmean compared with a bias of 0.8 for SUVmean)
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Fig. 3 Mean SUVmax (a) and TBRmax (b) in each individual patient (n= 34) on
18F-FDG PET/CT and PET/MRI. In all patients, SUVmax values were
higher on PET/CT, and in a majority of patients (n= 20), TBRmax values were higher on PET/MR
Table 4 Group analysis comparing patients with TBR(PET/CT) < TBR(PET/MRI) (group 1, n= 20) and patients with TBR(PET/CT) ≥TBR(PET/
MRI) (group 2, n= 14)
Parameter Group 1 Group 2 P valuea
Mean± SD Range Mean ± SD Range
SUVmax
PET/CT 3.1 ± 0.7 2.2 – 4.7 3.0 ± 0.4 2.5 – 3.7 0.5
PET/MRI 2.4 ± 0.7 1.7 – 4.5 2.2 ± 0.3 1.7 – 2.9 0.2
Blood pool
PET/CT 1.4 ± 0.3 1.1 – 2.0 1.4 ± 0.2 0.9 – 1.7 0.3
PET/MRI 1.0 ± 0.2 0.9 – 1.7 1.1 ± 0.2 0.8 – 1.4 0.6
TBRmax
PET/CT 2.1 ± 0.3 1.8 – 2.6 2.2 ± 0.3 1.7 – 2.7 0.5
PET/MRI 2.3 ± 0.3 1.9 – 2.8 2.1 ± 0.3 1.6 – 2.5 0.08
Circulation time (min)
PET/CT 74.6 ± 11.8 47 – 92 73.2 ± 11.6 55 – 92 0.7
PET/MRI 141.5 ± 19.8 101 – 173 132.7 ± 23.5 100 – 189 0.4
a One-way ANOVA
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reference. The main result was that quantification of FDG
uptake in the carotid arteries is feasible with integrated PET/
MRI, and TBR can be measured with similar accuracy to that
obtained with PET/CT. Qualitatively, this had already been
shown by one case study of simultaneous PET/MR imaging
and MR angiography of atherosclerotic plaque in the carotid
artery, which revealed significant 18F-FDG uptake in carotid
plaques [22]. Nevertheless, SUVmax values from PET/MR
were significantly lower than those from PET/CT, which is
in line with the results of previous studies comparing quanti-
tative values from PET/MR with those from PET/CT in on-
cological imaging. Underestimation of SUVmax on PET/MR
has been observed for different organs (liver, lung, spleen,
bone and muscle) [23].
Furthermore, in an initial feasibility study on the quantifi-
cation of vessel wall signals in carotid arteries of HIV patients
at increased risk of atherosclerosis, Ripa et al. found signifi-
cantly lower 18F-FDG SUVmean and SUVmax values on PET/
MRI than on PET/CT [24]. This difference in SUV may have
been for physiological and/or technical reasons. SUV is a
snapshot of the accumulated FDG in a certain region. As
FDG uptake is a dynamic process, SUV can change with time
after tracer injection [25]. Nevertheless, a previous study of
18F-FDG kinetics in atherosclerotic patients showed no signif-
icant differences in SUVmax and TBRmax values between 1
and 3 h after tracer injection [26]. Furthermore, in our study,
there was no significant difference in TBR values during the
same period. Therefore, a substantial physiological change in
SUV between 74±13 and 140±21 min after injection would
not be expected to cause the great differences in SUV found in
the present study. Blomberg et al. also demonstrated signifi-
cantly increased TBR on delayed 18FDG PET/CT (180 min)
compared with early imaging (90 min) due to the declining
blood pool and the extended uptake of tracer [27]. However,
in our study, we did not find significantly increased TBR
values on PET/MRI compared with PET/CT. To summarize,
in our study, there was a lower mean SUVmax and no signif-
icant increase in mean TBRmax values on later PET/MRI scans
compared with earlier PET/CTscans, which indicated system-
atic underestimations of both SUVand TBR in the evaluation
of plaque uptake. As shown in Table 4, patients with higher
TBRmax values on PET/MRI than on PET/CT showed lower
blood-pool activities and longer circulation times, on average.
This corresponds to previous findings [27].
Analysis of agreement between PET/CT and PET/MRI
measurements showed similar regression ratios for SUVmax
and TBRmax values between the two systems, whereas
Bland-Altman analysis demonstrated a lower bias of −0.07
for mean TBR compared with 0.8 for SUV, which indicates
a higher agreement between PET/CT and PET/MRI measure-
ment for TBR (Fig. 2).
Technical aspects affecting the SUV include differences in
the reconstructionmethod, postfiltering, partial volume effects
and differences in attenuation and scatter correction. The dif-
ferences in reconstruction in this study were minimal. Both
PET/CT and PET/MR images were reconstructed using an
OSEM algorithm with PSF correction developed by the same
vendor. The most prominent difference was the use of differ-
ent numbers of iterations for the convergence, and therefore
the recovery of activity was dependent on the number of iter-
ations, and, as shown by Hudson and Larkin [28], on the
product of iterations and subsets. A study by Knäusl et al.
[29] showed that between iteration–subset products of 84
and 64 there are differences of 1 – 9 % in the SUVmax for
spheres (11.5 – 0.3 ml in size) in a modified NEMA image
quality phantom. We used the same reconstruction algorithm
in our study for the PET/CT examinations. With regard to the
differences in postfiltering, a study by Tong et al. [30] found a
reduced contrast recovery of between 5 % and 8 % for spheres
of 10 – 22 mm in diameter for a similar reconstruction, after
applying a 4-mm FWHM gaussian filter.
Taking these findings into account, the underestimation of
SUV can be partially (we estimate around 10% of the mean of
25 %) explained by the differences in the reconstruction
methods used. The partial volume effect was not an issue in
the current study, as it is dependent on pixel size, and similar
pixel sizes were used for PET/CT and PET/MRI reconstruc-
tions. The main cause of the underestimation is thought to
have resulted from differences in AC. As bone is ignored on
standard MR-AC [17], and the proportion of bone is rather
high in the neck region, the omission of bone from AC could
cause a substantial under-correction of the activity values, and




Contralateral side Plaque P valuea Contralateral side Plaque P valuea
Mean± SD Range Mean ± SD Range Mean± SD Range Mean ± SD Range
SUV 2.5 ± 0.4 1.8 – 3.2 2.4 – 4.5) 2.4 – 4.5 <0.01 1.7 ± 0.3 1.2 – 2.3 2.3 ± 0.5 1.7 – 3.7 <0.01
TBR 1.7 ± 0.2 1.2 – 2.1 2.2 ± 0.3 1.7 – 2.7 <0.01 1.6 ± 0.3 1.1 – 1.9 2.2 ± 0.3 1.6 – 2.8 <0.01
a One-way ANOVA
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thus of the SUV [31]. A solution to the issue of inaccurate AC
in this case could be to use TBR rather than SUV. If the
reference region used to normalize lesion uptake is located
close to the lesion itself, similar underestimation can be
expected for both values, and therefore the underestimations
will cancel each other out, which is supported by the findings
of the present study. Moreover, SUV quantification in vessels
is affected by adjacent blood-pool activity. There is thus a
Fig. 4 Regression analysis between amount of radioactivity and circulation time (minutes). Both SUVmax and TBRmax of carotid plaque, on both PET/
CT and PET/MRI, showed an upward trend from early to late imaging time-points with continued decreasing activity as a result of blood clearance
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widely accepted consensus that TBR, which is corrected for
the interference of blood-pool activity, should be used instead
of SUV. For the calculation of TBR, we used the mean blood
activity from both internal jugular veins and external jugular
veins as the blood pool activity. To avoid registration prob-
lems, we chose the carotid bifurcation region for the present
study, because this region is particularly prone to plaque for-
mation [32], and enables high registration accuracy when es-
timating the colocalized uptake of 18F-FDG on PET/CT and
PET/MRI.
Considering the reduced radiation dose and superior lesion
discernment, PET/MRI might be used as an alternative to
PET/CT in the evaluation of carotid plaque lesions.
However, AC in PET/MRI is still challenging, and underesti-
mations of both SUV and TBR were observed in this study;
thus, a reliable quantitative criterion based on cut-off uptake
ratios for inflamed plaque is required. In addition, high cost, as
well as longer examination times, also limit the application of
PET/MRI.
There were several limitations to this study. First, the study
included a limited number of oncological patients, and there-
fore the findings might not be applicable to the general popu-
lation. Second, advanced morphological assessment of carotid
plaques was not performed. Third, histological or autoradio-
graphic validation of 18F-FDG uptake quantification in the ca-
rotid plaques could not be provided. Fourth, nonrandomization
of imaging sequences and distinct imaging reconstruction
methods may have caused confounded uptake ratios.
However, such studies have previously been published for
PET/CT evaluation [8], and this is why PET/CT was chosen
as the reference standard in the present study.
Conclusion
SUVmax and TBRmax values are the widely accepted reference
parameters for estimation of the radioactivity of atherosclerot-
ic plaques on PET/CT. However, due to systematic underesti-
mation of SUVmax and TBRmax on PET/MRI, the optimal cut-
off values indicating the presence of inflamed plaque tissue
need to be newly defined for PET/MRI.
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